全志科技(300458.SZ):擬出資2000萬元投資珠海志芯股權
格隆匯 4 月 11日丨全志科技(300458.SZ)公佈,為充分藉助專業投資機構的專業資源及其投資管理優勢,促進公司長遠發展,公司擬作為有限合夥人以自有資金出資2000萬元人民幣投資珠海志芯股權投資基金合夥企業(有限合夥)(“珠海志芯股權”)。
投資方向主要投資聚焦於集成電路行業,涵蓋智慧家庭、智慧汽車、人工智能、萬物互聯+萬物智能等下游應用方向的企業。
公司通過投資產業投資基金,依託基金合夥人的專業團隊優勢、項目資源優勢和平台優勢,積極尋找具有良好發展前景的項目,拓展投資渠道,提升公司綜合競爭能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.